News | November 07, 2025
Pfizer reports Q3 vaccine sales decline amid challenging US market conditions
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Anil Gupta has been appointed as the Senior Vice President, and Sanjay Singhania has taken charge as the Vice President of PHDCCI
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Subscribe To Our Newsletter & Stay Updated
